Moderna (MRNA) Projected to Post Quarterly Earnings on Friday

Moderna (NASDAQ:MRNA) will likely be issuing its quarterly earnings data before the market opens on Friday, February 14th. Analysts expect Moderna to post earnings of ($2.86) per share and revenue of $951.09 million for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

Moderna Trading Down 2.9 %

Shares of MRNA opened at $30.93 on Wednesday. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The firm has a 50-day moving average price of $39.77 and a 200 day moving average price of $56.76. Moderna has a 12-month low of $30.70 and a 12-month high of $170.47. The firm has a market capitalization of $11.90 billion, a P/E ratio of -5.31 and a beta of 1.59.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. JPMorgan Chase & Co. cut their price target on shares of Moderna from $59.00 to $45.00 and set an “underweight” rating for the company in a report on Tuesday, November 26th. Piper Sandler reissued an “overweight” rating and set a $69.00 target price (down previously from $115.00) on shares of Moderna in a research note on Monday, November 18th. Morgan Stanley decreased their price target on Moderna from $70.00 to $38.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 15th. UBS Group cut their price objective on Moderna from $108.00 to $96.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. Finally, Leerink Partners decreased their target price on shares of Moderna from $31.00 to $27.00 and set an “underweight” rating on the stock in a research report on Thursday, January 16th. Four equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $66.89.

Insider Transactions at Moderna

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the company’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the transaction, the insider now directly owns 19,717 shares of the company’s stock, valued at approximately $843,690.43. This represents a 6.71 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last ninety days, insiders sold 2,664 shares of company stock valued at $115,210. 15.20% of the stock is currently owned by corporate insiders.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.